VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

New review outlines role of extracellular vesicles in cancer and aging

A new review was published in Volume 13 of Oncoscience on September 30, 2026, titled "Extracellular vesicles in health, aging and disease."

6 Nov 2026

Norrin treatment prevents vision loss in diabetic rats

Over 100 million people in the U.S. are affected by diabetic retinopathy, a complication of diabetes that affects the eyes.

30 Oct 2026

Understanding the mechanisms of multilineage coordination during craniofacial development

The human face is one of the most complex structures formed during embryonic development. Its formation requires different cell populations to produce bones, muscles, nerves, blood vessels, teeth, and glands, all arranged in the correct positions and connected to perform their functions.

29 Oct 2026

Targeted drug combination extends survival in advanced kidney cancer

Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with the most common type of kidney cancer.

28 Oct 2026

Clues to prostate cancer risk in blood samples taken 15 years earlier

Recent study links blood proteins to aggressive prostate cancer, identifying potential biomarkers for early risk prediction and insights into immune activity.

26 Oct 2026

ECOG-ACRIN opens trial testing ivonescimab for aggressive bile duct cancer

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it will open a randomized, registration-enabling phase 2/3 clinical trial to evaluate ivonescimab combined with chemotherapy as first-line treatment for patients with advanced biliary tract cancer (BTC).

21 Oct 2026

A simple handgrip test offers new clues about long COVID

Weaker handgrip strength correlates with severe long COVID symptoms, highlighting its potential as a measure for muscle dysfunction and recovery challenges.

12 Oct 2026

Polymeric nanomedicine strategies improve solid tumor immunotherapy outcomes

Solid tumors are not merely collections of malignant cells but complex ecosystems comprising tumor cells, stromal cells, and the extracellular matrix (ECM).

9 Oct 2026

Disrupted circadian rhythms may influence tumor immunity and cancer spread

Epidemiological studies link light at night (LAN), shift work, chronic jet lag (CJL), and core clock gene mutations to higher cancer risk and aggressive spread, especially in breast and colorectal cancer.

8 Oct 2026

New study reveals how VEGF-C amplifies lymphangiogenic signaling

Lymphatic vessels act as the body's "drainage system," collecting excess fluid from tissues. When lymphatic drainage is impaired because lymphatic vessels are underdeveloped, damaged, or dysfunctional, lymphedema can develop, causing swelling, particularly in the arms and legs.

1 Oct 2026

Better fitness was linked to healthier brain structure, but not better memory

Researchers studying 353 cognitively unimpaired adults aged 60 to 94 found that higher muscular capacity was associated with lower basal ganglia perivascular space volume, while greater aerobic fitness was associated with greater gray matter volume and medial temporal lobe thickness. Fitness was not directly associated with global cognition or episodic memory, and evidence for cognitive reserve was limited, although VO₂max explained additional variation in delayed verbal memory beyond tau burden.

18 Sep 2026

Ivonescimab shows significant survival benefit for patients with PD-L1-positive NSCLC

Ivonescimab significantly prolonged overall survival compared with pembrolizumab as first-line treatment for patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), according to a prespecified interim analysis of the phase 3 HARMONi-2 trial presented today at the IASLC 2026 World Conference on Lung Cancer.

14 Sep 2026

Tumor DNA clearance reaches 39% in novel immunomodulator and ADC combination

The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase 1b/2 BNT324-01 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Capillaries drive new collateral artery formation after heart blockage

New research in mice challenges a long-standing view of how the heart builds backup blood vessels after a coronary artery blockage, showing that new collateral arteries arise primarily from capillaries rather than existing arteries.

20 Aug 2026

Glioma microenvironment emerges as key target for future therapies

The prognosis for glioma patients remains extremely poor despite aggressive multimodal standard therapy: maximal safe resection, radiotherapy, and temozolomide chemotherapy, with median survival rarely exceeding 15 to 18 months.

20 Aug 2026

Cosmetic microneedles deliver actives where creams struggle

This review shows how microneedle-based cosmetic systems bypass the stratum corneum to deliver poorly penetrating actives, including peptides, retinoids, vitamins, niacinamide, hyaluronic acid, and hair-growth compounds, into viable skin layers.

8 Jul 2026

New spatially resolved transcriptomic map reveals how bone and muscle cells communicate

A new study generated one of the most comprehensive spatially resolved transcriptomic maps of cellular communication between bone and skeletal muscle in a young mouse.

6 Jul 2026

Review explores complex associations between sleep apnea and lung cancer

Obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent hypoxia and sleep fragmentation, which may contribute to lung cancer development and progression.

29 May 2026

Cytokine-armored CAR-T cell therapy successfully attacks aggressive brain tumors in mice

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a new cytokine-armored CAR-T cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.

20 May 2026

Hyperbaric oxygen therapy shows dual effects in glioblastoma treatment

Glioblastoma remains a highly challenging malignancy with a pronounced tendency for recurrence. The hypoxic microenvironment is a key contributor to its therapy resistance.

23 Apr 2026